- DAWNZERA (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema Business Wire
- US FDA approves Ionis’ drug for rare genetic disorder Reuters
- FDA approves Ionis drug that prevents swelling attacks caused by a rare disease statnews.com
- FDA clears Ionis’ Dawnzera as first RNA-targeting preventative shot for HAE FirstWord Pharma
- FDA approves Ionis’ hereditary angioedema drug BioPharma Dive
Source link
